As of January 2025, efgartigimod is the only FcRn antagonist with registered (albeit in not all cases ongoing) trials within bullous pemphigoid, post-coronavirus disease 2019 (COVID-19) postural orthostatic tachycardia syndrome, membranous nephropathy, and antineutrophil cytoplasmic antibody-associated vasculitis, and disclosed development plans detail an investigation of efgartigimod within more than ten indications [245]
AOD-9604 Assay Design Considerations When incorporating AOD-9604 into a new lipolysis assay, researchers commonly include vehicle controls, a well-characterized positive control such as isoproterenol, and a dose range spanning two to three orders of magnitude
Disruptions in these hormonal rhythms are commonly observed with aging and have been associated with poorer sleep quality and circadian dysfunction
There is also a possibility that BPC-157 may play a role in addressing both acute and chronic inflammation, aiding in wound healing, and assisting in the healing of fractures, including cases of pseudoarthrosis
